Home
Name
AEE 788
Alternate Names
AEE-788
AEE788
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Tyrosine kinase inhibitor
NSC Number
None
Primary Site
Other cancer
Histology
None
Remarks
March 2015: several studies/clinical trials using this drug have been discontinued due to unacceptable toxicity.
Phase I TKI that blocks EGFR, erbB-2, and alsoVEGFR-1 and VEGFR-2..
Phase I TKI that blocks EGFR, erbB-2, and alsoVEGFR-1 and VEGFR-2..
Coding
This drug should be coded
